Aim: To evaluate the efficacy and safety of the vaginal-specific lactobacilli strain in management of bacterial vaginosis (BV). Materials and methods: A nonrandomized, open-labeled, noncomparative, multicentric study was conducted in a total of 58 female patients suffering from BV. Each patient was administered a combination of four strains of lactobacilli. Vaginal pH, discharge, odor, itching, and painful urination were performed at baseline, week 2, and week 4 as assessment parameters. Results: At the end of the study, data were extractable in only 56 females (mean age was 34.57 ± 11 years). Associated BV symptoms like vaginal discharge, odor, and painful urination reduced significantly at week 4 as compared to baseline. The most frequently encountered symptoms were vaginal discharge, vaginal pH, odor, and itching. With a shift in pH < 4.5, at the end of week 4 all females showed improvement in the vaginal microbiota. Tolerability of fixed-dose combination was found to be good and none of the subjects discontinued the treatment. Conclusion: Probiotic combination of vaginal-specific probiotic strains was found to be effective and safe for use in females who suffer from BV. Clinical significance: Lactobacilli have been found in very low numbers in women suffering from BV. After supplementing probiotic, mere fall in pH < 4.5 indicates probable colonization of the vagina with a specific strain of lactobacilli has helped in production of lactic acid and restoration of the vaginal microflora.